KalVista Pharmaceuticals Inc. (NASDAQ: KALV) Attends 31st Annual ROTH Conference
KalVista Pharmaceuticals (NASDAQ: KALV) is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE)and diabetic macular edema (DME). The company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors and is advancing multiple drug candidates for…







